Non-viral delivery of RNA for therapeutic T cell engineering

• Published in: Advanced drug delivery reviews 2024-05, Vol.208, p.115215, Article 115215
• Main Authors: Berdecka, Dominika, De Smedt, Stefaan C., De Vos, Winnok H., Braeckmans, Kevin
• Format: Article
• Language: English
• Subjects: Cancer immunotherapy; Cell engineering; Cell Engineering - methods; Cell therapy; Gene therapy; Humans; Immunotherapy, Adoptive - methods; Neoplasms - pathology; Non-viral delivery; RNA - metabolism; RNA therapeutics; T cell; T-Lymphocytes
• ISSN: 0169-409X; 1872-8294; 1872-8294
• DOI: 10.1016/j.addr.2024.115215

[Display omitted] Adoptive T cell transfer has shown great success in treating blood cancers, resulting in a growing number of FDA-approved therapies using chimeric antigen receptor (CAR)-engineered T cells. However, the effectiveness of this treatment for solid tumors is still not satisfactory, emphasizing the need for improved T cell engineering strategies and combination approaches. Currently, CAR T cells are mainly manufactured using gammaretroviral and lentiviral vectors due to their high transduction efficiency. However, there are concerns about their safety, the high cost of producing them in compliance with current Good Manufacturing Practices (cGMP), regulatory obstacles, and limited cargo capacity, which limit the broader use of engineered T cell therapies. To overcome these limitations, researchers have explored non-viral approaches, such as membrane permeabilization and carrier-mediated methods, as more versatile and sustainable alternatives for next-generation T cell engineering. Non-viral delivery methods can be designed to transport a wide range of molecules, including RNA, which allows for more controlled and safe modulation of T cell phenotype and function. In this review, we provide an overview of non-viral RNA delivery in adoptive T cell therapy. We first define the different types of RNA therapeutics, highlighting recent advancements in manufacturing for their therapeutic use. We then discuss the challenges associated with achieving effective RNA delivery in T cells. Next, we provide an overview of current and emerging technologies for delivering RNA into T cells. Finally, we discuss ongoing preclinical and clinical studies involving RNA-modified T cells.